DAY THREE 5 APRIL

DC Co-conference Day 3 April 5

Cancer Vaccines Continued

Case Studies In Vaccine Safety

Preventing Nosocomial Infections & Hard to Develop Vaccine

The Future of Supply Chains

The Rise of AMR: Vaccine Development Against Bacterial Infections

Vaccines for Neglected and Bacterial Diseases

The role of vaccines in preventing AMR

Analysing Immune Profiles for Cancer Treatment

Enabling Technologies from Discovery to Market

Cancer & Immunotherapy
09:10

DNA vaccines for cancer immunotherapy

  • Introduction to DNA plasmid and electroporation delivery technology
  • Updates in proof of concept studies from various trials
  • Head and neck cancer, bladder cancer, prostate cancer
  • Examples of potential combination partners
  • The regulatory landscape for DNA Vaccines
Vaccine Supply & Logistics
09:10

Lessons learnt in successful distribution of Malaria Vaccines in Africa

Influenza & Respiratory
09:10

Results on developing a new pertussis vaccine – Opportunities for maternal

·         The need for a new pertussis vaccine with longer lasting immunity

·         Challenges in making an effective pertussis vaccines: Cyclical by nature, waning immunity, asymptomatic carriers

Clinical Trials
09:10

Using a core endotoxin vaccine (J5) to fight the increasing spread of multidrug-resistant (MDR) gram-negative bacterial (GNB) infections

  • Directing a vaccine against the conserved LPS core (lipooligosaccharide, LOS) region of GNBs as a highly effective and protective target
  • Two Ph1 trials showing how well-tolerated and non-reactogenic the vaccine was as well as high immunogenic levels when administered with CPG 7909 adjuvant
  • Future applications to generate antibodies for the treatment of a broad range of MDR GNB infections
  • How could the vaccine affect the microbiome?
Emerging & Re-emerging Diseases
09:10

Will a new 2018 global leadership commit to NTDs?

·         How will the shift in global governance from 2017 (in the UN, WHO, US president and UK prime minister) affect the global support for NTDs?

·         What does our community of NTD scientists, public health experts, and health care providers want this new global leadership to know about our diseases?

·         What should they prioritize?

Veterinary
09:10

Role of vaccines in preventing further AMR - The big push

  • What are the incentives for industry?
  • Proposed diseases where development or improvement of vaccines would have a high impact on antibiotic use
  • Creating global vaccine research networks to pull resources and expertise to address gaps for priority diseases
Immune Profiling
09:10

Panel: Engineering CAR-T & TCR cells for cancer therapy

  • How can you additionally modify T-cells beyond the T cell receptor/ the CAR to behave in a more controlled and/or potent fashion?
  • The challenge of keeping the manufacturing process simple, whilst maintaining the effectiveness of the product
  • The use of molecular imaging to track CAR T cells: Where do they go in the body? Do they accumulate in the tumor?
  • Mitigating side effects: controlling neurotoxicity etc.
  • Biomarkers – Identifying patients that will respond to treatment
  • Combination strategies
Emerging & Re-emerging Diseases
09:40

Bioconjugate Shigella vaccine in clinical development

·         The development plan for a Shigella vaccine demonstrated in PhI and a PhIIB human challenge study

·         A regulatory tool for licensing

Vaccine Supply & Logistics
09:40

Challenges in supply chain security: implementing serialization

Cancer & Immunotherapy
09:40

Overcoming the limitations of viral vectors whilst still maintaining superior generation and expansion of CTLs

Vaccine Safety & Pharmacovigilance
09:40

The science of causality assessment

  • The science of causality assessment is poorly understood by healthcare providers and the general public
  • Temporal relationships and hypotheses regarding mechanisms are not sufficient to establish causality
  • Journals should establish standard criteria for publishing case reports of alleged causal relationships
  • Decisions to compensate for alleged vaccine injuries should be based on science
  • Safety profiles may vary in different populations
  • All countries should have formal vaccine safety programs
Veterinary
09:40

Advancements made in bacterial vaccines

  • Technologies for identification of antigens
  • Novel vaccine formulations

Oncoviruses

Influenza & Respiratory
10:10

The prevention and control of pneumococcal diseases

Cancer & Immunotherapy
10:10

Updates in the clinical development of an immunotherapy candidate for the treatment of chronic Hepatitis B

Veterinary
10:10

How early stage vaccine application aids decrease in the use of antibiotics, either for preventive or curative purposes in poultry

  • Benefits of early control in immunosuppressive poultry diseases
  • Application of vaccines at early stages of development, for example day 18 of age embryos for in ovo, or day old at hatch  
Emerging & Re-emerging Diseases
10:25

HiA; A vaccine solution to address an urgent public health need

Dr Andrew Cox, Senior Research Officer, National Research Council
10:40

Networking coffee break

Clinical Trials
11:30

Clinical progression in vaccine, anti-fungal and microbiome approaches to tackling candida albicans infections

Vaccine Supply & Logistics
11:30

Panel: Innovation, emerging technology and digitalization in vaccine supply chains

Panellists to be announced shortly
Cancer & Immunotherapy
11:30

Translational Studies Informing the Design and Feasibility of a vaccine against Epstein Barr Virus

  • Opportunities for the development of a vaccine against EBV
  • Understanding the medical necessity, market potential and public health use of EBV Vaccine.
  • The science behind the 3 vaccine candidates that currently exist:
    • Pre-clinical safety data
    • Updates on progress of phase 1 trials.
Veterinary
11:30

Panel:Alternatives to Antibiotics: Issues and opportunities from funders’ perspective

  • How to incentivise vet pharma companies to produce new veterinary products to reduce AMR resistance
  • Marketing the science and the costs associated with this
  • Statement of societal goals that the funding entity would like to accomplish
  • Political feasibility of incentive mechanisms (e.g., is a program that gives money to large pharma companies likely to be accepted by legislators?)
  • Economics of incentive mechanisms (e.g., which incentive ‘lever’ can be pushed for maximal effect?  What would unintended consequences of such incentives be?)
Immune Profiling
11:30

Cancer neoantigens and their use in personalized cancer vaccines

Influenza & Respiratory
12:00

Presenting early stage development of a vaccine to prevent the bacterial infections that exacerbate Chronic Obstructive Pulmonary Disease (COPD)

·         COPD is a very common, chronic, progressive, respiratory illness of adults, which can be triggered by bacterial infections

·         A vaccine to prevent these respiratory infections could modify the clinical progression of COPD, and improve quality of life

Emerging & Re-emerging Diseases
12:00

Strategies for developing vaccines against Paratyphoid A fever

Clinical Trials
12:00

Tools to assess and advance Group A Streptococcus (GAS) Vaccines

Immune Profiling
12:00

Development of off-the-shelf immunotherapy from pluripotent cells

  • Pluripotent Cell Derived T and NK cells: Cornerstone Approach for Off-the-Shelf Cancer Immunotherapy
  • Use of small molecules and biologics, ex vivo, to optimize the biological properties and therapeutic function of hematopoietic cells
12:30

Networking Lunch & Poster Session

AFTERNOON PLENARY OF CONGRESS

last published: 12/Dec/17 15:15 GMT